{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "February 2021: 42-year-old female, light smoker (9 pack/years), presented with stage IV adenocarcinoma of the lung (T1cN3M1c (HEP, OSS, PLE, LYM)).",
        "clinical_data": {
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "9 pack/years"
            }
          ],
          "diagnoses": [
            {
              "code": "C0009404",
              "label": "Adenocarcinoma of lung",
              "status": "active",
              "onset_date": "2021-02"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Patient developed a deep venous thrombosis and a pulmonary embolism. While on therapeutic anticoagulation, the patient developed multiple intracerebral infarcts necessitating treatment with both low molecular heparin and ASS.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0012539",
              "label": "Deep Venous Thrombosis",
              "status": "active"
            },
            {
              "code": "C0033860",
              "label": "Pulmonary Embolism",
              "status": "active"
            },
            {
              "code": "C0021842",
              "label": "Infarction, Cerebral",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "Low Molecular Weight Heparin",
              "modality": "subcutaneous",
              "indication": "Deep Venous Thrombosis"
            },
            {
              "drug": "Acetylsalicylic Acid",
              "indication": "Infarction, Cerebral"
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 3,
        "content": "Initial molecular diagnostic was performed using PCR-based methods covering the hotspots in EGFR, KRAS and BRAF and immunohistochemistry analysis (IHC) for PD-L1, ALK and ROS1 due to limited and sparse FFPE tissue. PDL-1 status TPS: 80%. High ROS1-expression in the cytoplasm of tumor cells.",
        "clinical_data": {
          "labs": [
            {
              "test": "PD-L1",
              "value": "80",
              "unit": "%",
              "flag": "unknown"
            }
          ],
          "diagnoses": [
            {
              "code": "C4024734",
              "label": "High ROS1 expression",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 5,
        "content": "February 24th 2021: Patient started crizotinib treatment based on positive IHC result. February 25th 2021: Hybrid capture-based NGS analysis (HC-NGS) was reported on a pre-therapeutically taken pleural. Analysis confirmed ROS1 positivity and revealed a CD74-ROS1 translocation (C7:R34) and an additional nonsense mutation in TP53.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0886993",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": "2021-02-24",
              "end_date": null,
              "indication": null
            }
          ],
          "labs": [
            {
              "test": "C4025580",
              "value": "positive",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": "2021-02-25"
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "CD74-ROS1 translocation",
              "status": "active",
              "onset_date": "2021-02-25"
            },
            {
              "code": null,
              "label": "nonsense mutation in TP53",
              "status": "active",
              "onset_date": "2021-02-25"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 8,
        "content": "Eight weeks after the start of crizotinib, a CT scan revealed good partial remission of all tumor sites. 4 months after the start of crizotinib therapy, the patient progressed, in particular with histologically confirmed hepatic metastases. June 2021.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0886328",
              "start_date": null,
              "end_date": null
            }
          ],
          "imaging": [
            {
              "type": "C0009026",
              "modality": "CT",
              "date": null,
              "finding": "partial remission of all tumor sites"
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "hepatic metastases",
              "status": "active",
              "onset_date": "2021-06"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Patient developed a deep venous thrombosis and a pulmonary embolism while on anticoagulation, leading to multiple intracerebral infarcts and treatment with low molecular heparin and ASS."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Molecular diagnostic testing performed via PCR and IHC due to limited tissue. Results showed PDL-1 TPS of 80% and high ROS1 expression."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Patient started crizotinib treatment based on positive IHC result. NGS analysis confirmed ROS1 positivity and revealed a CD74-ROS1 translocation and a TP53 mutation.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0886993"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "After initial partial remission on crizotinib, the patient progressed with histologically confirmed hepatic metastases.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [
            "C0009026"
          ],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    }
  ]
}